Literature DB >> 22405276

Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial.

Peter Sandercock1, Richard Lindley, Joanna Wardlaw, Will Whiteley, Gordon Murray.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22405276     DOI： 10.1111/j.1747-4949.2012.00782.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN： 1747-4930            Impact factor:   5.266


× No keyword cloud information.
  17 in total

1.  Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane Review: PROS.

Authors:  Stefano Ricci; Silvia Cenciarelli; Tatiana Mazzoli
Journal:  Intern Emerg Med       Date:  2013-08-23       Impact factor: 3.397

2.  Ischaemic stroke and thrombolysis: ask the onset time, not the age!

Authors:  Silvia Cenciarelli; Tatiana Mazzoli; Stefano Ricci
Journal:  Intern Emerg Med       Date:  2012-11-25       Impact factor: 3.397

3.  Stroke: Expanded indications for stroke thrombolysis--what next?

Authors:  Geoffrey A Donnan; Stephen M Davis
Journal:  Nat Rev Neurol       Date:  2012-07-31       Impact factor: 42.937

4.  Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.

Authors:  William N Whiteley; Douglas Thompson; Gordon Murray; Geoff Cohen; Richard I Lindley; Joanna Wardlaw; Peter Sandercock
Journal:  Stroke       Date:  2014-03-06       Impact factor: 7.914

5.  Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).

Authors:  William N Whiteley; Douglas Thompson; Gordon Murray; Geoff Cohen; Richard I Lindley; Joanna Wardlaw; Peter Sandercock
Journal:  Stroke       Date:  2014-11-04       Impact factor: 7.914

6.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

7.  Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.

Authors: 
Journal:  Lancet Neurol       Date:  2015-03-27       Impact factor: 44.182

8.  Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.

Authors: 
Journal:  Lancet Neurol       Date:  2013-06-21       Impact factor: 44.182

9.  Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke.

Authors:  Simiao Wu; Grant Mair; Geoff Cohen; Zoe Morris; Anders von Heijne; Nick Bradey; Lesley Cala; Andre Peeters; Andrew J Farrall; Alessandro Adami; Gillian Potter; Ming Liu; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw
Journal:  Stroke Vasc Neurol       Date:  2020-11-27

Review 10.  Thrombolysis for acute ischaemic stroke.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory J del Zoppo
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.